Candesartan doses in excess of the recommended antihypertensive maxima have been reported to lead to greater reductions of proteinuria than the advised doses. High-dose angiotensin-converting-enzyme inhibitors, however, are at least as effective as high-dose angiotensin blockers and less expensive. Angiotensin-converting-enzyme inhibition is thus the first-line strategy to halt kidney disease progression.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The role of renin angiotensin system inhibition in kidney repair
Fibrogenesis & Tissue Repair Open Access 04 May 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. doi:10.1681/ASN.2008040416 (2009).
Hollemberg, N. K. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 25, 1921–1926 (2007).
Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288–296 (2006).
Ruggenenti, P., Perna, A., Remuzzi, G. & GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 63, 2254–2261 (2003).
Ruggenenti, P., Perna, A., Gherardi, G., Benini, R. & Remuzzi, G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 35, 1155–1165 (2000).
Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889–1898 (2007).
Ruggenenti, P. et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107, 586–592 (2003).
Catapano, F. et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am. J. Kidney Dis. 52, 475–485 (2008).
Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094–1103 (2003).
Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213–1224 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ruggenenti, P., Cravedi, P. & Remuzzi, G. Increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 5, 367–368 (2009). https://doi.org/10.1038/nrneph.2009.77
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.77
This article is cited by
-
Achieving remission of proteinuria in childhood CKD
Pediatric Nephrology (2017)
-
The role of renin angiotensin system inhibition in kidney repair
Fibrogenesis & Tissue Repair (2010)
-
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Nature Reviews Nephrology (2010)
